Cargando…

Analysis of risk factors for neurological symptoms in patients with purely hepatic Wilson’s disease at diagnosis

OBJECTIVE: To analyze and explore the risk factors for neurological symptoms in patients with purely hepatic Wilson's disease (WD) at diagnosis. METHODS: This retrospective study was conducted at the First Affiliated Hospital of the Guangdong Pharmaceutical University on 68 patients with purely...

Descripción completa

Detalles Bibliográficos
Autores principales: Diao, Sheng-Peng, Zhuang, Yang-Sha, Huang, Ye-Qing, Zhou, Zhi-Hua, Liu, Ai-Qun, Hong, Ming-Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972690/
https://www.ncbi.nlm.nih.gov/pubmed/36855079
http://dx.doi.org/10.1186/s12883-023-03105-w
_version_ 1784898371870261248
author Diao, Sheng-Peng
Zhuang, Yang-Sha
Huang, Ye-Qing
Zhou, Zhi-Hua
Liu, Ai-Qun
Hong, Ming-Fan
author_facet Diao, Sheng-Peng
Zhuang, Yang-Sha
Huang, Ye-Qing
Zhou, Zhi-Hua
Liu, Ai-Qun
Hong, Ming-Fan
author_sort Diao, Sheng-Peng
collection PubMed
description OBJECTIVE: To analyze and explore the risk factors for neurological symptoms in patients with purely hepatic Wilson's disease (WD) at diagnosis. METHODS: This retrospective study was conducted at the First Affiliated Hospital of the Guangdong Pharmaceutical University on 68 patients with purely hepatic WD aged 20.6 ± 7.2 years. The physical examinations, laboratory tests, color Doppler ultrasound of the liver and spleen, and magnetic resonance imaging (MRI) of the brain were performed. RESULTS: The elevated alanine transaminase (ALT) and aspartate transaminase (AST) levels and 24-h urinary copper level were higher in the purely hepatic WD who developed neurological symptoms (NH-WD) group than those in the purely hepatic WD (H-WD) group. Adherence to low-copper diet, and daily oral doses of penicillamine (PCA) and zinc gluconate (ZG) were lower in the NH-WD group than those in the H-WD group. Logistic regression analysis showed that insufficient doses of PCA and ZG were associated with the development of neurological symptoms in patients with purely hepatic WD at diagnosis. CONCLUSION: The development of neurological symptoms in patients with purely hepatic WD was closely associated with insufficient doses of PCA and ZG, and the inferior efficacy of copper-chelating agents. During the course of anti-copper treatment, the patient's medical status and the efficacy of copper excretion should be closely monitored.
format Online
Article
Text
id pubmed-9972690
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99726902023-03-01 Analysis of risk factors for neurological symptoms in patients with purely hepatic Wilson’s disease at diagnosis Diao, Sheng-Peng Zhuang, Yang-Sha Huang, Ye-Qing Zhou, Zhi-Hua Liu, Ai-Qun Hong, Ming-Fan BMC Neurol Research OBJECTIVE: To analyze and explore the risk factors for neurological symptoms in patients with purely hepatic Wilson's disease (WD) at diagnosis. METHODS: This retrospective study was conducted at the First Affiliated Hospital of the Guangdong Pharmaceutical University on 68 patients with purely hepatic WD aged 20.6 ± 7.2 years. The physical examinations, laboratory tests, color Doppler ultrasound of the liver and spleen, and magnetic resonance imaging (MRI) of the brain were performed. RESULTS: The elevated alanine transaminase (ALT) and aspartate transaminase (AST) levels and 24-h urinary copper level were higher in the purely hepatic WD who developed neurological symptoms (NH-WD) group than those in the purely hepatic WD (H-WD) group. Adherence to low-copper diet, and daily oral doses of penicillamine (PCA) and zinc gluconate (ZG) were lower in the NH-WD group than those in the H-WD group. Logistic regression analysis showed that insufficient doses of PCA and ZG were associated with the development of neurological symptoms in patients with purely hepatic WD at diagnosis. CONCLUSION: The development of neurological symptoms in patients with purely hepatic WD was closely associated with insufficient doses of PCA and ZG, and the inferior efficacy of copper-chelating agents. During the course of anti-copper treatment, the patient's medical status and the efficacy of copper excretion should be closely monitored. BioMed Central 2023-02-28 /pmc/articles/PMC9972690/ /pubmed/36855079 http://dx.doi.org/10.1186/s12883-023-03105-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Diao, Sheng-Peng
Zhuang, Yang-Sha
Huang, Ye-Qing
Zhou, Zhi-Hua
Liu, Ai-Qun
Hong, Ming-Fan
Analysis of risk factors for neurological symptoms in patients with purely hepatic Wilson’s disease at diagnosis
title Analysis of risk factors for neurological symptoms in patients with purely hepatic Wilson’s disease at diagnosis
title_full Analysis of risk factors for neurological symptoms in patients with purely hepatic Wilson’s disease at diagnosis
title_fullStr Analysis of risk factors for neurological symptoms in patients with purely hepatic Wilson’s disease at diagnosis
title_full_unstemmed Analysis of risk factors for neurological symptoms in patients with purely hepatic Wilson’s disease at diagnosis
title_short Analysis of risk factors for neurological symptoms in patients with purely hepatic Wilson’s disease at diagnosis
title_sort analysis of risk factors for neurological symptoms in patients with purely hepatic wilson’s disease at diagnosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972690/
https://www.ncbi.nlm.nih.gov/pubmed/36855079
http://dx.doi.org/10.1186/s12883-023-03105-w
work_keys_str_mv AT diaoshengpeng analysisofriskfactorsforneurologicalsymptomsinpatientswithpurelyhepaticwilsonsdiseaseatdiagnosis
AT zhuangyangsha analysisofriskfactorsforneurologicalsymptomsinpatientswithpurelyhepaticwilsonsdiseaseatdiagnosis
AT huangyeqing analysisofriskfactorsforneurologicalsymptomsinpatientswithpurelyhepaticwilsonsdiseaseatdiagnosis
AT zhouzhihua analysisofriskfactorsforneurologicalsymptomsinpatientswithpurelyhepaticwilsonsdiseaseatdiagnosis
AT liuaiqun analysisofriskfactorsforneurologicalsymptomsinpatientswithpurelyhepaticwilsonsdiseaseatdiagnosis
AT hongmingfan analysisofriskfactorsforneurologicalsymptomsinpatientswithpurelyhepaticwilsonsdiseaseatdiagnosis